Ipca Laboratories Limited (IPCALAB.BO)
INR 1363.95
(4.85%)
INR 1363.95
(4.85%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 5.47 Billion INR | 16.13% |
| 2022 | 4.71 Billion INR | -46.69% |
| 2021 | 8.84 Billion INR | -22.45% |
| 2020 | 11.4 Billion INR | 88.02% |
| 2019 | 6.06 Billion INR | 36.3% |
| 2018 | 4.44 Billion INR | 85.79% |
| 2017 | 2.39 Billion INR | 23.07% |
| 2016 | 1.94 Billion INR | 102.22% |
| 2015 | 962 Million INR | -62.88% |
| 2014 | 2.59 Billion INR | -45.81% |
| 2013 | 4.78 Billion INR | 47.44% |
| 2012 | 3.24 Billion INR | 17.43% |
| 2011 | 2.76 Billion INR | 5.09% |
| 2010 | 2.62 Billion INR | 27.98% |
| 2009 | 2.05 Billion INR | 103.73% |
| 2008 | 1 Billion INR | -25.84% |
| 2007 | 1.35 Billion INR | 7.74% |
| 2006 | 1.26 Billion INR | 105.15% |
| 2005 | 615 Million INR | -16.99% |
| 2004 | 740.85 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.92 Billion INR | 222.6% |
| 2023 Q2 | 1.45 Billion INR | -10.91% |
| 2023 Q1 | 1.62 Billion INR | 112.78% |
| 2023 FY | 5.47 Billion INR | 16.13% |
| 2023 Q3 | 1.79 Billion INR | 24.0% |
| 2023 Q4 | 595.9 Million INR | -66.87% |
| 2022 Q1 | 1.43 Billion INR | 9.85% |
| 2022 Q3 | 1.07 Billion INR | -25.06% |
| 2022 Q4 | 765.2 Million INR | -29.04% |
| 2022 Q2 | 1.43 Billion INR | 0.59% |
| 2022 FY | 4.71 Billion INR | -46.69% |
| 2021 FY | 8.84 Billion INR | -22.45% |
| 2021 Q2 | 2.5 Billion INR | -18.4% |
| 2021 Q3 | 1.96 Billion INR | -21.29% |
| 2021 Q4 | 1.3 Billion INR | -33.88% |
| 2021 Q1 | 3.06 Billion INR | 90.07% |
| 2020 FY | 11.4 Billion INR | 88.02% |
| 2020 Q4 | 1.61 Billion INR | -39.22% |
| 2020 Q3 | 2.65 Billion INR | -0.6% |
| 2020 Q2 | 2.67 Billion INR | -40.14% |
| 2020 Q1 | 4.46 Billion INR | 418.7% |
| 2019 FY | 6.06 Billion INR | 36.3% |
| 2019 Q3 | 1.97 Billion INR | 2.35% |
| 2019 Q4 | 860.1 Million INR | -56.47% |
| 2019 Q1 | 1.29 Billion INR | 31.54% |
| 2019 Q2 | 1.93 Billion INR | 48.94% |
| 2018 Q2 | 1.18 Billion INR | 72.92% |
| 2018 FY | 4.44 Billion INR | 85.79% |
| 2018 Q4 | 985.5 Million INR | -38.09% |
| 2018 Q3 | 1.59 Billion INR | 34.29% |
| 2018 Q1 | 685.5 Million INR | 0.0% |
| 2017 FY | 2.39 Billion INR | 23.07% |
| 2016 FY | 1.94 Billion INR | 102.22% |
| 2015 FY | 962 Million INR | -62.88% |
| 2014 FY | 2.59 Billion INR | -45.81% |
| 2013 FY | 4.78 Billion INR | 47.44% |
| 2012 FY | 3.24 Billion INR | 17.43% |
| 2011 FY | 2.76 Billion INR | 5.09% |
| 2010 FY | 2.62 Billion INR | 27.98% |
| 2009 FY | 2.05 Billion INR | 103.73% |
| 2008 FY | 1 Billion INR | -25.84% |
| 2007 FY | 1.35 Billion INR | 7.74% |
| 2006 FY | 1.26 Billion INR | 105.15% |
| 2005 FY | 615 Million INR | -16.99% |
| 2004 FY | 740.85 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 11.119% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 82.75% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | -16.238% |
| Granules India Limited | 4.05 Billion INR | -35.045% |
| Indoco Remedies Limited | 984.6 Million INR | -455.91% |
| Achyut Healthcare Limited | 5.73 Million INR | -95390.23% |
| Ajanta Pharma Limited | 8.16 Billion INR | 32.937% |
| Alkem Laboratories Limited | 17.95 Billion INR | 69.52% |
| Alpa Laboratories Limited | 167.76 Million INR | -3162.599% |
| Brooks Laboratories Limited | -195.91 Million INR | 2893.757% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | -238.895% |
| Bajaj HealthCare Limited | -837.93 Million INR | 753.216% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -625.408% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 90.17% |
| Eris Lifesciences Limited | 3.91 Billion INR | -39.636% |
| FDC Limited | 3.05 Billion INR | -79.328% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 136.449% |
| Gufic Biosciences Limited | 861.35 Million INR | -535.452% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | -30.024% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -2336.674% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 2874.427% |
| Lasa Supergenerics Limited | -217.3 Million INR | 2618.798% |
| Laurus Labs Limited | 1.6 Billion INR | -240.922% |
| Lupin Limited | 19.14 Billion INR | 71.41% |
| Mankind Pharma Limited | 19.12 Billion INR | 71.386% |
| Medicamen Biotech Limited | 109.31 Million INR | -4907.319% |
| Medico Remedies Limited | 82.9 Million INR | -6501.816% |
| Megasoft Limited | -127.46 Million INR | 4394.086% |
| NATCO Pharma Limited | 13.88 Billion INR | 60.574% |
| Piramal Pharma Limited | 178.2 Million INR | -2971.549% |
| RPG Life Sciences Limited | 876.6 Million INR | -524.401% |
| Sigachi Industries Limited | 571.8 Million INR | -857.237% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 94.284% |
| Suven Pharmaceuticals Limited | 3 Billion INR | -82.28% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -2062.225% |
| Unichem Laboratories Limited | -704.74 Million INR | 876.666% |
| Wanbury Limited | 559.56 Million INR | -878.174% |
| Windlas Biotech Limited | 581.87 Million INR | -840.674% |
| ZIM Laboratories Limited | 172.46 Million INR | -3073.706% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 85.818% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 241.356% |
| Divi's Laboratories Limited | 16 Billion INR | 65.791% |
| Hester Biosciences Limited | 188.89 Million INR | -2797.718% |
| Procter & Gamble Health Limited | 2 Billion INR | -172.341% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -1117.074% |
| Bal Pharma Limited | 73.92 Million INR | -7304.426% |
| Strides Pharma Science Limited | -706.14 Million INR | 875.13% |
| Venus Remedies Limited | 284.9 Million INR | -1821.146% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | -152.349% |
| Nectar Lifesciences Limited | 49.95 Million INR | -10857.958% |
| Shilpa Medicare Limited | 318.74 Million INR | -1617.22% |
| Aarti Drugs Limited | 1.71 Billion INR | -219.307% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | -307.164% |
| Suven Life Sciences Limited | -1.05 Billion INR | 620.907% |
| Ind-Swift Limited | 142.31 Million INR | -3746.1% |
| Valiant Laboratories Limited | 3.19 Million INR | -171160.951% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 0.955% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 196.468% |
| Themis Medicare Limited | 435.23 Million INR | -1157.588% |
| Hikal Limited | 696.02 Million INR | -686.4% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 66.955% |
| Sequent Scientific Limited | -358.69 Million INR | 1625.97% |
| Novartis India Limited | 851.9 Million INR | -542.505% |
| Wockhardt Limited | -4.63 Billion INR | 218.218% |
| Jubilant Pharmova Limited | 771 Million INR | -609.922% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -77078.511% |
| Neuland Laboratories Limited | 3 Billion INR | -82.402% |
| Morepen Laboratories Limited | 961.59 Million INR | -469.208% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -3648.613% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 6133.599% |